Skip to content

Dual Reinforcement Contingency Management for Alcohol Use Disorders

Dual Reinforcement Contingency Management for Alcohol Use Disorders

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04064463
Acronym
Peth
Enrollment
74
Registered
2019-08-22
Start date
2020-01-22
Completion date
2025-11-25
Last updated
2026-02-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alcohol Use Disorder, Contingency Management

Brief summary

Phosphatidylethanol (PEth) is a direct biomarker of alcohol that can detect moderate to heavy drinking with high sensitivity and specificity over 3-week periods. Reinforcing negative PEth results alongside attendance may increase the proportion of participants who respond to CM during and post treatment. In the proposed study, the investigators will collect PEth samples every 3 weeks for 12 weeks in 150 participants initiating outpatient treatment for alcohol use disorders. Using a two-group randomized design, participants will be assigned to standard care with PEth monitoring alone or with CM for attending treatment and submitting PEth negative samples. Compared to standard care and monitoring, the investigators expect that the CM intervention will result in greater attendance, more PEth negative samples, and higher proportions of self-reported non-drinking days, along with lower proportions of heavy drinking days, over the short term and the long term, measured throughout a 12-month follow-up. The investigators anticipate that the reinforcement intervention may decrease other drug use and sexual risk behaviors that spread HIV, reduce psychiatric symptoms, and improve quality of life as well.

Interventions

BEHAVIORALStandard care

standard treatment for substance use disorders, along with sample monitoring

BEHAVIORALContingency management

Participants can earn reinforcement for attending group and abstinence from alcohol

Sponsors

UConn Health
Lead SponsorOTHER
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
CollaboratorNIH

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* in intensive outpatient treatment * DSM-5 diagnosis of an alcohol use disorder

Exclusion criteria

* have a condition that may hinder study participation

Design outcomes

Primary

MeasureTime frameDescription
Group attendance12 weekslongest consecutive days attended groups
Alcohol abstinence12 weeksnumber of negative PEth samples

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORSheila Alessi, Ph.D.

UConn Health

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 10, 2026